ArticleAnnals of medicine and surgery (2012)2026
Bacterial extracellular vesicles and microbial-derived small RNAs as circulating cancer biomarkers.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Kaposi sarcoma in the era of immunodeficiency: challenges and opportunities for treatment and prevention.Annals of medicine and surgery (2012) · 2026Article
- Bacterial and gut microbiota-derived extracellular vesicles as emerging sources of cancer biomarkers: molecular mechanisms, diagnostic approaches, and therapeutic applications.Frontiers in cellular and infection microbiology · 2026Review
- Bacterial extracellular vesicles as central mediators of microbiota-host communication.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggests that bacterial extracellular vesicles (BEVs) and microbial-derived small RNAs (msRNAs) in human plasma represent a new class of circulating cancer biomarkers. Multi-cohort analyses of more than 1100 patients revealed 2.8- to 3.5-fold higher BEV levels in cancer cases versus controls, with microbial RNA cargo comprising up to 1.6% of total plasma RNA. Specific BEV-msRNA panels achieved area under the curve values of 0.87-0.94 for early-stage cancer detection, outperforming conventional CEA and CA19-9 markers. Functionally, BEV-associated msRNAs modulate tumor-related signaling by activating NF-κB and STAT3 pathways and suppressing TP53/PTEN expression, promoting cytokine release and oncogenic inflammation. BEVs also exhibit superior stability remaining detectable for more than 72 hours in circulation supporting their feasibility for clinical liquid biopsy. Collectively, circulating BEVs and msRNAs offer promising, mechanism-linked biomarkers for non-invasive cancer detection and precision monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.